Amplia Therapeutics (ASX:ATX) stopped further recruitment in the Amplicity clinical trial following three dose-limiting toxicities, according to a Tuesday filing with the Australian bourse.

The trial is investigating the company's lead drug narmafotinib in combination with the chemotherapy regimen modified Folfirinox in advanced pancreatic cancer, the filing said.

Among the eight patients, three events of protocol-defined dose-limiting toxicities have been observed relating to the chemotherapy regimen.

The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring, per the filing.

The company's shares tumbled 25% in recent Tuesday trade.